Empagliflozin/Linagliptin
Glyxambi is a prescription brand-name medication combining two glucose-lowering agents used to treat type 2 diabetes in adults. It contains empagliflozin, an SGLT2 inhibitor that helps the kidneys remove glucose from the body through urine, and linagliptin, a DPP-4 inhibitor that increases insulin release after meals. This combination is prescribed when diet, exercise, and single-agent diabetes medications are insufficient to control blood sugar levels.
Glyxambi is a dual-action type 2 diabetes medication combining an SGLT2 inhibitor and DPP-4 inhibitor to help improve blood sugar control in adults.
Key facts at a glance
- RxNorm
- 1602110
- Generic
- Glyxambi
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Glyxambi is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It may be used as initial therapy for patients needing better blood sugar control or for those already taking one of its component medications.
Glyxambi combines two complementary mechanisms: empagliflozin blocks SGLT2 proteins in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion; linagliptin inhibits DPP-4 enzymes, thereby increasing insulin secretion and suppressing glucagon release in a glucose-dependent manner after meals.
Glyxambi is not recommended for patients with type 1 diabetes or diabetic ketoacidosis. Common side effects may include urinary tract and genital infections due to increased glucose in urine. Rare but serious risks include pancreatitis and Fournier's gangrene. Patients should stay well-hydrated and inform their healthcare provider of any history of kidney problems, bladder infections, or heart failure. Safety during pregnancy has not been established.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy